The RESTORE study is investigating whether semaglutide or metformin can help restore ovulation and improve reproductive health in adolescents and adults with PMOS and obesity
Clinical trials have demonstrated that tirzepatide can reduce hemoglobin A1c by up to 2.5% in type 2 diabetes, with weight loss typically ranging from 5-10% in diabetes patients and 15-20% in those treated specifically for obesity
For instance, a 2015 study found that Ozempic (semaglutide) did not affect the levels of oral birth control available in the bloodstream
Therefore, to clarify whether the function of GLP-1R is activated or inhibited in CM, we detected the changes in the level of endogenous GLP-1, a natural agonist of GLP-1R, in the TNC in NTG-induced CM mice
Additionally, Novo Nordisk will present mid-stage Phase 2 results for zenagamtide, an investigational peptide therapy targeting metabolic disorders
These results rank among the most dramatic weight-loss outcomes ever reported in a late-stage clinical study and signal a paradigm shift in how meaningful benefit is defined across metabolic and related chronic diseases